gsk201604296k.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 29 April 2016
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 


 GlaxoSmithKline plc
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons
 
In accordance with DTR 3.1.4R(1)(a) and (c) I give details of changes in the interests of the following Directors and Persons Discharging Managerial Responsibilities ('PDMR') who acquired Ordinary Shares ('Shares') in GlaxoSmithKline plc ('GSK') at a price of 1496.49 pence per Share, following the re-investment of the dividend paid to shareholders on 14 April 2016.
 
 
 
Director/PDMR
 
 
Shares
Sir Andrew Witty
 
2,257.407
Mr R Connor
552.391
Mr S A Hussain
1,460.067
Mr D S Redfern
2,129.312
Dr M M Slaoui
4.719
Ms C Thomas
2,692.384
Mr P C Thomson
1,002.153
Dr P J T Vallance
 
3,827.535
Ms E Walmsley
 
2,705.444
 
 
 
Connected Person
 
Shares
Mrs K Thomson (Connected Person to Mr P C Thomson)
 
251.103
 
GSK was informed of these allocations on 28 April 2016.
 
 
V A Whyte
Company Secretary
 
29 April 2016
 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: April 29, 2016 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc